Company Overview

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for Alzheimer’s disease. The company’s core scientific approach centers on selective targeting of soluble amyloid-beta oligomers (AβOs), which it believes are among the primary neurotoxic drivers of cognitive decline associated with Alzheimer’s disease. Acumen operates within the biotechnology and central nervous system (CNS) therapeutics industries, with its primary value driver tied to the advancement of its lead investigational drug candidate, sabirnetug (previously referred to as ACU193).

The company primarily serves the neurology and neurodegenerative disease treatment market, with an emphasis on patients in early-stage Alzheimer’s disease. Acumen’s positioning is differentiated by its focus on selective oligomer targeting rather than broader amyloid plaque removal approaches used by some competing therapies. The company was founded in 1996 and evolved from a broader biotechnology research platform into a neuroscience-focused organization concentrated on Alzheimer’s therapeutics development. Its business model is centered on clinical development, intellectual property generation, and potential future commercialization or strategic partnerships.

Business Operations

Acumen Pharmaceuticals operates primarily as a single-segment biotechnology company focused on research and development activities. Revenue generation has historically been limited because the company remains in the clinical development stage and does not currently market approved products. Operations are largely concentrated on advancing sabirnetug (ACU193) through clinical trials, including studies evaluating safety, tolerability, biomarker activity, and cognitive outcomes in Alzheimer’s disease patients. The company’s principal assets include its antibody platform, related intellectual property portfolio, clinical development programs, and scientific expertise in amyloid-beta oligomer biology.

The company’s operational footprint is concentrated in the United States, though clinical trial activities involve collaboration with research institutions, clinical investigators, and service providers across multiple regions. Acumen relies on contract research organizations and manufacturing partners for portions of its development and production activities. Strategic collaborations include relationships with academic and clinical research institutions involved in Alzheimer’s disease research. Public filings and company disclosures identify clinical development infrastructure and proprietary therapeutic targeting technology as central operational assets.

Strategic Position & Investments

Acumen’s strategic direction is focused on advancing disease-modifying therapies for Alzheimer’s disease through precision targeting of toxic amyloid-beta oligomers. The company’s primary growth initiative is the continued clinical advancement of sabirnetug, including expansion into later-stage clinical studies if ongoing data support efficacy and safety objectives. The company has invested heavily in neuroscience research capabilities, biomarker development, and clinical trial execution intended to support regulatory progression and potential future commercialization opportunities.

The company has not historically operated a diversified portfolio of commercial subsidiaries or broad investment holdings typical of larger pharmaceutical firms. Instead, its strategic value is concentrated in its intellectual property estate, clinical pipeline, and scientific differentiation within Alzheimer’s therapeutics. Acumen participates in the broader emerging neurodegenerative disease treatment sector, where interest in biomarker-guided therapies and targeted biologics has increased significantly. Public disclosures indicate that the company continues evaluating opportunities for partnerships, financing, and clinical expansion aligned with its lead therapeutic program.

Geographic Footprint

Acumen Pharmaceuticals is headquartered in Charlottesville, Virginia, with operations primarily centered in the United States. Its clinical development activities extend through collaborations with trial sites, researchers, and vendors across multiple regions involved in Alzheimer’s disease research and patient recruitment. The company’s operational infrastructure is comparatively lean relative to large multinational pharmaceutical companies, reflecting its status as a clinical-stage biotechnology organization.

Although Acumen does not maintain a broad international commercial presence, its therapeutic focus addresses a global healthcare market due to the worldwide prevalence of Alzheimer’s disease. Clinical and scientific engagement may involve institutions and investigators in North America and other research-intensive healthcare markets. The company’s influence internationally is currently driven more by its scientific and clinical development activities than by direct commercial operations.

Leadership & Governance

Acumen Pharmaceuticals’ leadership team is composed of biotechnology and neuroscience executives with backgrounds in drug development, clinical operations, finance, and commercialization. Corporate governance is overseen by a board of directors and executive leadership team focused on advancing Alzheimer’s disease therapeutics through clinical validation and capital discipline. Public company disclosures emphasize scientific rigor, patient-focused development, and long-term value creation through differentiated neuroscience innovation.

Key executives include:

• Daniel O’Connell – President and Chief Executive Officer
• Eric Siemers, M.D. – Chief Medical Officer
• Matt Lorberbaum – Chief Financial Officer
• Karin Walker – Chief Legal Officer and Corporate Secretary

The company’s leadership strategy has consistently emphasized advancing selective amyloid-beta oligomer targeting as a differentiated scientific pathway within Alzheimer’s disease treatment development, while maintaining operational focus on clinical execution, regulatory engagement, and preservation of financial resources.